Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a ...

The increasing demand for gene therapy and CRISPR technology increases the genome engineering.Dublin, Feb. 12, 2025 (GLOBE ...

Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...

Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim ...

Boehringer Ingelheim and ExpressionEdits will collaborate on the optimization of the expression of gene therapies ExpressionEdits announced a collaboration and licensing agreement with Boehringer ...

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...

Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...

Ingelheim, Germany Saturday, February 15, 2025, 12:00 Hrs [IST] ...

Boehringer Ingelheim India and EMRI Green Health Services partner to improve stroke care through specialized training and ...

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...